Twenty-four months progression-free survival (ongoing) for treatment of recurrent ovarian clear cell carcinoma with surufatinib in combination with toripalimab: a case report

Read full text Summarise with VIRAT
Authors: Siyi Liu, Yi Fu, Ke Zuo, Wei J. Chen, Xiaojun Chen, Boer Shan, Huijuan Yang, Shuang Ye
Cited by: 0
References: 27

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Recurrent ovarian clear cell carcinoma (OCCC) remains a therapeutic challenge due to intrinsic chemoresistance and paucity of targeted options. Surufatinib is a multi-target tyrosine kinase inhibitor that may enhance antitumor immunity when combined with PD-1 blockade. We report a 53-year-old female with recurrent OCCC who developed a platinum-sensitive first relapse (platinum-free interval, 9.8 months) after adjuvant platinum-based chemotherapy and achieved a 24-month progression-free survival (ongoing) on surufatinib plus toripalimab. The best response was partial response, and treatment was well tolerated except for Grade 1 hemoptysis and Grade 1–2 proteinuria. Radiologic disease control was durable. However, because biomarker assessment relevant to immune checkpoint inhibition was not performed, the biological basis of response remains uncertain. This case suggests the clinical feasibility of surufatinib plus toripalimab and its association with durable disease control in an individual patient with recurrent OCCC. However, given the platinum-sensitive nature of the relapse, treatment efficacy should be interpreted cautiously. Further prospective studies incorporating biomarker assessment are warranted.

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment Endometrial and Cervical Cancer Treatments PARP inhibition in cancer therapy

Publication details

Journal / source
BMC Women s Health
Volume
26
Issue
1
Publication date
27 March 2026
Language
EN